These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 2975535

  • 1. Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.
    Yamaguchi S, Onji M, Kondoh H, Miyaoka H, Ohta Y.
    Clin Exp Immunol; 1988 Oct; 74(1):1-6. PubMed ID: 2975535
    [Abstract] [Full Text] [Related]

  • 2. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.
    Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G.
    J Immunol; 1994 Mar 15; 152(6):3074-87. PubMed ID: 7511637
    [Abstract] [Full Text] [Related]

  • 3. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2865-75. PubMed ID: 2993418
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F, Raspadori D, Ventura MA, Rondelli D, Zinzani PL, Gherlinzoni F, Miggiano MC, Fiacchini M, Rosti G, Rizzi S, Tura S.
    Bone Marrow Transplant; 1996 Jul 15; 18(1):79-85. PubMed ID: 8831999
    [Abstract] [Full Text] [Related]

  • 6. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M, Hasegawa H, Nakayabu M, Fukai K, Suzuki S.
    J Clin Lab Immunol; 1993 Jul 15; 40(2):47-60. PubMed ID: 7932628
    [Abstract] [Full Text] [Related]

  • 7. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM, Ibayashi Y, Tokuda Y, Colquhoun SD, Holmes EC, Golub SH.
    Cancer Res; 1988 Mar 01; 48(5):1180-3. PubMed ID: 3257716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K, Tilden AB, Balch CM.
    J Immunol; 1986 May 15; 136(10):3910-5. PubMed ID: 3084648
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.
    Attallah AM, Tabll AA, El-Sadany M, Ibrahim TA, El-Dosoky I.
    Clin Exp Med; 2003 Nov 15; 3(3):181-5. PubMed ID: 14648234
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C.
    J Biol Response Mod; 1988 Oct 15; 7(5):457-72. PubMed ID: 3263471
    [Abstract] [Full Text] [Related]

  • 13. Lymphocyte profiles in patients with chronic low back pain enrolled in a clinical trial.
    Brennan PC, Graham MA, Triano JJ, Hondras MA, Anderson RJ.
    J Manipulative Physiol Ther; 1994 May 15; 17(4):219-27. PubMed ID: 8046277
    [Abstract] [Full Text] [Related]

  • 14. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 15. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
    Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL.
    J Biol Response Mod; 1987 Aug 15; 6(4):412-29. PubMed ID: 3498011
    [Abstract] [Full Text] [Related]

  • 16. Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B.
    Eggink HF, Houthoff HJ, Huitema S, Wolters G, Poppema S, Gips CH.
    Clin Exp Immunol; 1984 Apr 15; 56(1):121-8. PubMed ID: 6713726
    [Abstract] [Full Text] [Related]

  • 17. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K, Tilden AB, Kumagai K, Balch CM.
    J Immunol; 1985 Feb 15; 134(2):802-7. PubMed ID: 3917475
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Large granular lymphocytes are central cells in the interleukin-2-dependent differentiation pathway of natural killer cells.
    Lange A, Ernst M, Jaźwiec B, Ennen J, Flad HD.
    Nat Immun Cell Growth Regul; 1987 Feb 15; 6(5):237-49. PubMed ID: 3502170
    [Abstract] [Full Text] [Related]

  • 20. Immunoregulatory T subsets in chronic active viral hepatitis: characterization by monoclonal antibodies.
    Pignata C, Vajro P, Troncone R, Monaco G, Ciriaco M.
    J Pediatr Gastroenterol Nutr; 1983 May 15; 2(2):229-33. PubMed ID: 6223993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.